m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00217)
Name
2-Deoxyglucose
Synonyms
2-DG; 2-DG (epilepsy), NeurogenomeX; 2-DG (epilepsy), NeurogenomeX); 2-deoxy-D-glucose; D-arabinohexose; Dextrose; Glucose; University of Wisconsin-Madison/NeuroGenomeX
    Click to Show/Hide
Status
Phase 1/2
Structure
Formula
C6H12O5
InChI
1S/C6H12O5/c7-2-1-4(9)6(11)5(10)3-8/h2,4-6,8-11H,1,3H2/t4-,5-,6+/m1/s1
InChIKey
VRYALKFFQXWPIH-PBXRRBTRSA-N
PubChem CID
108223
VARIDT Drug ID
DR00011
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Glucose transporter type 1 (SLC2A1)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for 2-Deoxyglucose. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 2-Deoxyglucose through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for 2-Deoxyglucose. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of 2-Deoxyglucose through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Glucose transporter type 1 (SLC2A1) is a therapeutic target for 2-Deoxyglucose. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of 2-Deoxyglucose through regulating the expression of Glucose transporter type 1 (SLC2A1). [1], [2]
References
Ref 1 m(6)A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer. 2020 Apr 3;19(1):72. doi: 10.1186/s12943-020-01190-w.
Ref 2 Glutamine 161 of Glut1 glucose transporter is critical for transport activity and exofacial ligand binding. J Biol Chem. 1994 Aug 12;269(32):20533-8.